InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,426.00
(
0.12%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.79
(
1.05%
)
Bitcoin
65,172.14
(
-1.98%
)
Post# of 252253
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119875
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 178755

Monday, 10/06/2014 12:36:55 PM

Monday, October 06, 2014 12:36:55 PM

Post# of 252253
TEVA ends R&D in cancer and women’s health:

http://in.reuters.com/article/2014/10/06/us-teva-pharm-ind-research-idINKCN0HV16G20141006

Teva Pharmaceutical Industries said it will stop research and development in areas such as oncology and women's health to cut costs, though it will maintain a commercial presence in these areas.

The world's biggest generic drugmaker will discontinue or divest from 14 projects in its pipeline, the Israeli company said on Monday. These projects amount to more than $150 million in R&D costs in 2015 and more than $200 million for each of 2016 and 2017.

These cost savings will be directed, in part, to increasing resources in Teva's core therapeutic areas - central nervous system (CNS) and respiratory…

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up